nect Biopharma (US:CNTB) ZACKS·2025-07-30 17:00Company Overview - Connect Biopharma Holdings Limited Sponsored ADR (CNTB) currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), which is supported by a historical track record of outperforming the market [4] Price Performance - CNTB shares have increased by 29.07% over the past week, significantly outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 1.8% during the same period [6] - Over the past month, CNTB's price change is 65.09%, compared to the industry's 5.63% [6] - In the last quarter, CNTB shares have surged by 120.96%, and over the past year, they have gained 47.06%, while the S&P 500 has only moved 14.96% and 18.01%, respectively [7] Trading Volume - The average 20-day trading volume for CNTB is 262,215 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, one earnings estimate for CNTB has moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$1.12 to -$0.90 [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [10] Conclusion - Given the strong price performance, positive earnings outlook, and high Momentum Style Score, CNTB is positioned as a promising investment opportunity [12]